That's not actually the case. The IPO only placed 20% of the Company for A$125M which at A$2 per share equated to a market cap of A$625M.At ~A$0.50 per share the market cap is still ~A$150M; well above their residual cash backing of ~A$70M.
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game